Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.
On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.
Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.
Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.
Veracyte (Nasdaq: VCYT) reported preliminary, unaudited results for Q4 and full-year 2025. Key highlights: Q4 total revenue $138M–$140M (+16%–18%); FY2025 total revenue $515M–$517M (+~16%); FY testing revenue $491M–$493M (+17%–18%); FY testing volume ~169,700 (+19%). Decipher volume ~102,000 (+27%) and Afirma volume ~67,700 (+11%). Veracyte expects adjusted EBITDA margin >25% for 2025 and issues 2026 guidance of $570M–$582M (10%–13% growth) with testing revenue guidance of $559M–$569M (14%–16%).
Veracyte (Nasdaq: VCYT) will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 9:45 a.m. PT. Management's live audio webcast will be available at the company's investor website, and a replay will be accessible for 30 days after the live broadcast.
Investors can listen via the investor events page at http://investor.veracyte.com/events-presentations.
Veracyte (Nasdaq: VCYT) will participate in three investor conferences in November 2025 with scheduled fireside chats and live webcasts.
- Wolfe Research Healthcare Conference — New York: Fireside chat on November 17, 2025 at 10:00 a.m. ET
- Jefferies Global Healthcare Conference — London: Fireside chat on November 20, 2025 at 11:30 a.m. GMT
- Stephens Annual Investment Conference — Nashville: Fireside chat on November 20, 2025 at 11:00 a.m. CT
Live audio webcasts will be available at http://investor.veracyte.com/events-presentations, and replays will be accessible for 90 days after each live broadcast.
Veracyte (Nasdaq: VCYT) reported Q3 2025 results with total revenue of $131.9M (up 14%) and testing revenue of $127.8M (up 17%). Testing volume rose 19% to 43,679 tests; total volume rose 18% to 45,888 tests. GAAP net income was $19.1M (15% of revenue) and adjusted EBITDA was $39.7M or 30.1% of revenue. Cash, cash equivalents and short-term investments totaled $366.4M at quarter end, with cash from operations of $44.8M in the quarter.
The company raised full-year 2025 guidance to testing revenue $484M–$487M and total revenue $506M–$510M, and raised adjusted EBITDA margin guidance to over 25%. Key product and clinical milestones and launches were also highlighted.
Veracyte (NASDAQ: VCYT) announced two publications (Nov 3, 2025) showing research use of the Afirma GRID whole-transcriptome tool to derive mRNA signatures that may preoperatively stratify thyroid nodule cancer risk.
Key findings: researchers analyzed 445 Afirma GSC-tested samples and screened 30 molecular signatures; an "invasion signature" associated with a 30% greater likelihood of intermediate/high-risk cancer, while a "NIS expression" signature predicted low-risk cancers. Authors say further validation is required before clinical use.
Veracyte (Nasdaq: VCYT) will release its third quarter 2025 financial results after market close on Tuesday, November 4, 2025.
Management will host a conference call and live webcast to discuss results and provide a business update at 4:30 p.m. Eastern Time the same day. The live webcast link is https://edge.media-server.com/mmc/p/kcexjtb4. A replay will be available on the investor site at https://investor.veracyte.com/events-presentations. Dial-in access requires registration via the company’s investor portal.
Veracyte (NASDAQ:VCYT) announced groundbreaking results from the BALANCE trial, validating that their PAM50 molecular biomarker can predict hormone therapy effectiveness in recurrent prostate cancer patients. The study, presented at ASTRO 2025, demonstrated that among 127 patients with luminal B tumors, 72% taking apalutamide with salvage radiation therapy avoided biochemical failure, compared to 54% in the placebo group.
The prospective validation trial involved 295 men with non-metastatic prostate cancer following prostate removal surgery. The PAM50 biomarker, available through Veracyte's Decipher GRID platform, represents the first predictive biomarker validated in a prospective, randomized trial for non-metastatic prostate cancer, marking a significant advancement in personalized treatment approaches.
This breakthrough enables more precise selection of patients who would benefit from hormone therapy, potentially helping others avoid unnecessary treatment and side effects. The study results are part of 9 Decipher-focused abstracts being presented at the conference.
Veracyte (NASDAQ:VCYT) announced that groundbreaking data validating a molecular signature for predicting hormone therapy effectiveness in recurrent prostate cancer patients will be presented at ASTRO 2025. The research, conducted using Veracyte's Decipher GRID tool, is part of nine Decipher-focused abstracts to be presented at the conference.
The presentations include a significant double-blinded placebo-controlled biomarker trial of Apalutamide and radiotherapy, along with an analysis of adverse molecular features across over 200,000 patients. The conference will be held from September 27 to October 1 at the Moscone Center in San Francisco.
Veracyte (NASDAQ:VCYT) announced that 12 Afirma-related abstracts will be presented at the 2025 American Thyroid Association Annual Meeting in Scottsdale, Arizona from September 10-14. The research presentations leverage the company's Afirma Genomic Resource for Intelligent Discovery (GRID), which represents the world's largest molecular database for thyroid nodules.
The presentations include studies on cell-surface targets in thyroid tumors, mRNA expression signatures for predicting histopathology, molecular profiling comparisons between Black and White patients, and genomic landscape analysis of thyroid nodules in elderly patients. These studies stem from Veracyte's extensive database of thyroid-nodule whole-transcriptome-derived genomic profiles, which the company makes available to eligible researchers.
Veracyte (NASDAQ:VCYT) announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a fireside chat on September 9, 2025, at 4:50 p.m. Eastern Time. Investors can access a live audio webcast of the presentation through Veracyte's investor relations website, with the replay remaining available for 90 days following the event.
FAQ
What is the current stock price of Veracyte (VCYT)?
What is the market cap of Veracyte (VCYT)?
